Literature DB >> 34121311

RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss.

Yan Hu1,2, Xiaoqun Li2, Xin Zhi2,3, Wei Cong1, Biaotong Huang1, Huiwen Chen2, Yajun Wang2, Yinghua Li1, Lipeng Wang4, Chao Fang2, Jiawei Guo2, Ying Liu1, Jin Cui2, Liehu Cao5, Weizong Weng2, Qirong Zhou2, Sicheng Wang6, Xiao Chen2,7, Jiacan Su1,2,8.   

Abstract

Receptor activator of NF-κB ligand (RANKL) is essential for osteoclast formation and bone remodeling. Nevertheless, the cellular source of RANKL for osteoclastogenesis has not been fully uncovered. Different from peripheral adipose tissue, bone marrow (BM) adipose lineage cells originate from bone marrow mesenchymal stromal cells (BMSCs). Here, we demonstrate that adiponectin promoter-driven Cre expression (AdipoqCre ) can target bone marrow adipose lineage cells. We cross the AdipoqCre mice with ranklfl/fl mice to conditionally delete RANKL from BM adipose lineage cells. Conditional deletion of RANKL increases cancellous bone mass of long bones in mice by reducing the formation of trabecular osteoclasts and inhibiting bone resorption but does not affect cortical bone thickness or resorption of calcified cartilage. AdipoqCre ; ranklfl/fl mice exhibit resistance to estrogen deficiency and rosiglitazone (ROS)-induced trabecular bone loss but show bone loss induced by unloading. BM adipose lineage cells therefore represent an essential source of RANKL for the formation of trabecula osteoclasts and resorption of cancellous bone during remodeling under physiological and pathological conditions. Targeting bone marrow adiposity is a promising way of preventing pathological bone loss.
© 2021 The Authors.

Entities:  

Keywords:  RANKL; bone marrow adipose lineage cell; bone remodeling; osteoclast

Mesh:

Year:  2021        PMID: 34121311      PMCID: PMC8406405          DOI: 10.15252/embr.202152481

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   9.071


  46 in total

1.  The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.

Authors:  P P Geusens; R B M Landewé; P Garnero; D Chen; C R Dunstan; W F Lems; P Stinissen; D M F M van der Heijde; S van der Linden; M Boers
Journal:  Arthritis Rheum       Date:  2006-06

2.  Macrophage-lineage TRAP+ cells recruit periosteum-derived cells for periosteal osteogenesis and regeneration.

Authors:  Bo Gao; Ruoxian Deng; Yu Chai; Hao Chen; Bo Hu; Xiao Wang; Shouan Zhu; Yong Cao; Shuangfei Ni; Mei Wan; Liu Yang; Zhuojing Luo; Xu Cao
Journal:  J Clin Invest       Date:  2019-04-04       Impact factor: 14.808

3.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

4.  Role of androgen receptor on cyclic mechanical stretch-regulated proliferation of C2C12 myoblasts and its upstream signals: IGF-1-mediated PI3K/Akt and MAPKs pathways.

Authors:  Yiming Ma; Shaoting Fu; Lin Lu; Xiaohui Wang
Journal:  Mol Cell Endocrinol       Date:  2017-04-26       Impact factor: 4.102

5.  Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.

Authors:  Qiang Fu; Robert L Jilka; Stavros C Manolagas; Charles A O'Brien
Journal:  J Biol Chem       Date:  2002-10-02       Impact factor: 5.157

6.  Endothelial proteolytic activity and interaction with non-resorbing osteoclasts mediate bone elongation.

Authors:  Sara G Romeo; Khadija M Alawi; Julia Rodrigues; Amit Singh; Anjali P Kusumbe; Saravana K Ramasamy
Journal:  Nat Cell Biol       Date:  2019-04-01       Impact factor: 28.824

7.  Matrix-embedded cells control osteoclast formation.

Authors:  Jinhu Xiong; Melda Onal; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Nat Med       Date:  2011-09-11       Impact factor: 53.440

8.  RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation.

Authors:  Xiao Chen; Xin Zhi; Jun Wang; Jiacan Su
Journal:  Bone Res       Date:  2018-11-27       Impact factor: 13.362

9.  Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.

Authors:  Cristina Sobacchi; Annalisa Frattini; Matteo M Guerrini; Mario Abinun; Alessandra Pangrazio; Lucia Susani; Robbert Bredius; Grazia Mancini; Andrew Cant; Nick Bishop; Peter Grabowski; Andrea Del Fattore; Chiara Messina; Gabriella Errigo; Fraser P Coxon; Debbie I Scott; Anna Teti; Michael J Rogers; Paolo Vezzoni; Anna Villa; Miep H Helfrich
Journal:  Nat Genet       Date:  2007-07-15       Impact factor: 38.330

10.  Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss.

Authors:  Jinhu Xiong; Keisha Cawley; Marilina Piemontese; Yuko Fujiwara; Haibo Zhao; Joseph J Goellner; Charles A O'Brien
Journal:  Nat Commun       Date:  2018-07-25       Impact factor: 14.919

View more
  18 in total

Review 1.  Bone marrow adiposity during pathologic bone loss: molecular mechanisms underlying the cellular events.

Authors:  Jiao Li; Lingyun Lu; Yi Liu; Xijie Yu
Journal:  J Mol Med (Berl)       Date:  2021-11-09       Impact factor: 4.599

Review 2.  Exercise to Mend Aged-tissue Crosstalk in Bone Targeting Osteoporosis & Osteoarthritis.

Authors:  Sarah E Little-Letsinger; Janet Rubin; Brian Diekman; Clinton T Rubin; Cody McGrath; Gabriel M Pagnotti; Eric L Klett; Maya Styner
Journal:  Semin Cell Dev Biol       Date:  2021-09-04       Impact factor: 7.727

Review 3.  Distinct Metabolism of Bone Marrow Adipocytes and their Role in Bone Metastasis.

Authors:  Yixuan Li; Shan Cao; Anastasia Gaculenko; Yifan Zhan; Aline Bozec; Xiaoxiang Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-21       Impact factor: 6.055

Review 4.  Silk fibroin-based biomaterials for cartilage/osteochondral repair.

Authors:  Ziyang Zhou; Jin Cui; Shunli Wu; Zhen Geng; Jiacan Su
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

5.  Babam2 negatively regulates osteoclastogenesis by interacting with Hey1 to inhibit Nfatc1 transcription.

Authors:  Fujun Jin; Yexuan Zhu; Meijing Liu; Rongze Wang; Yi Cui; Yanting Wu; Gang Liu; Yifei Wang; Xiaogang Wang; Zhe Ren
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

Review 6.  The "Three in One" Bone Repair Strategy for Osteoporotic Fractures.

Authors:  Xiao Chen; Yan Hu; Zhen Geng; Jiacan Su
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

Review 7.  Advances in the application of mesenchymal stem cells, exosomes, biomimetic materials, and 3D printing in osteoporosis treatment.

Authors:  Xiao-Yu He; Hai-Ming Yu; Shu Lin; Yi-Zhong Li
Journal:  Cell Mol Biol Lett       Date:  2021-11-14       Impact factor: 5.787

8.  Flavonoid Phloretin Inhibits Adipogenesis and Increases OPG Expression in Adipocytes Derived from Human Bone-Marrow Mesenchymal Stromal-Cells.

Authors:  Antonio Casado-Díaz; Ángel Rodríguez-Ramos; Bárbara Torrecillas-Baena; Gabriel Dorado; José Manuel Quesada-Gómez; María Ángeles Gálvez-Moreno
Journal:  Nutrients       Date:  2021-11-22       Impact factor: 5.717

9.  RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss.

Authors:  Yan Hu; Xiaoqun Li; Xin Zhi; Wei Cong; Biaotong Huang; Huiwen Chen; Yajun Wang; Yinghua Li; Lipeng Wang; Chao Fang; Jiawei Guo; Ying Liu; Jin Cui; Liehu Cao; Weizong Weng; Qirong Zhou; Sicheng Wang; Xiao Chen; Jiacan Su
Journal:  EMBO Rep       Date:  2021-06-13       Impact factor: 9.071

Review 10.  Bone Marrow Mesenchymal Stromal Cells: Identification, Classification, and Differentiation.

Authors:  Qianmin Gao; Lipeng Wang; Sicheng Wang; Biaotong Huang; Yingying Jing; Jiacan Su
Journal:  Front Cell Dev Biol       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.